South Rampart Pharma

11:00 AM - 12:00 PM (PDT), Tuesday, June 14, 2022
As current medications are either highly addictive or cause harm to the liver and kidney, there is a tremendous unmet need for a new safe, effective and non-opioid pain medication. We are developing a novel non-narcotic small molecule, SRP-3D (DA), with a markedly safer liver profile than what is currently available for the potential treatment of pain without the risks of abuse or liver toxicity. In 2021, the FDA IND opened and we are currently in the clinic with Phase 1 trials. To date, we’ve raised $7.75M, including funding for the entire Ph 1 trial. Our work is also funded by a current NIH/NINDS STTR ‘fast-track’ grant. Unlike acetaminophen, our lead asset SRP-3D (DA) does not generate the toxic metabolite to cause liver toxicity and we have also discovered the mechanism for pain relief in the nociception area of the brain. These known mechanisms significantly de-risk the planned Phases 1 and 2a trials. Currently, we are steering our efforts to find the right partner to support Ph 2a clinical trials for neuropathic pain, pain in patients with liver disease, and a Ph 1 using an IV formulation for acute pain.
CEO and Co-founder of South Rampart Pharma; Professor of Surgery, Innovation
Ochsner Health